Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1200265 | 0.97 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL726263 | 0.92 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL3278054 | 0.92 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL7421159 | 0.92 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL121087 | 0.86 | — | — | |
| SCHEMBL9640691 | 0.86 | — | — | |
| SCHEMBL7279427 | 0.86 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL9640680 | 0.86 | — | — | |
| SCHEMBL1133414 | 0.84 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL7783728 | 0.84 | ALDH1A1 (0.38) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6670433-B2 | Useful as molding resins | E. I. DU PONT DE NEMOURS AND COMPANY | 2003-12-30 | — | — | US | claimed |
| US-20030055186-A1 | Polymers of substituted cyclopentenes | MCLAIN STEPHAN J (US) | 2003-03-20 | — | — | US | claimed |
| US-6258908-B1 | Polymers of substituted cyclopentenes | E. I. DU PONT DE NEMOURS AND COMPANY | 2001-07-10 | — | — | US | claimed |
| EP-1068247-A2 | POLYMERS OF SUBSTITUTED CYCLOPENTENES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2001-01-17 | — | — | EP | claimed |
| WO-1999050320-A2 | POLYMERS OF SUBSTITUTED CYCLOPENTENES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1999-10-07 | — | — | WO | claimed |
| US-20140221478-A1 | DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | VIROBAY, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8748649-B2 | Di-fluoro containing compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20140018421-A1 | DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | VIROBAY, INC. (US) | 2014-01-16 | — | — | US | disclosed |
| US-8367732-B2 | Di-fluoro containing compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20110172310-A1 | DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | VIROBAY, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| US-7893112-B2 | N-(1-cyanocyclopropyl)-4,4-difluoro-2(S)-[2,2,2-trifluoro-1(S)-(4-fluorophenyl)ethylamino)octamide; rheumatoid arthritis, multiple sclerosis, myasthenia gravis, psoriasis, pemphigus vulgaris, Graves' disease, myasthenia gravis, lupus, asthma, pain, atherosclerosis; cathepsins B, K, L, F, and S inhibitors | VIROBAY, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| EP-2262370-A1 | DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | Virobay, Inc. (US) | 2010-12-22 | — | — | EP | disclosed |
| WO-2005028429-A2 | HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
| WO-2004108661-A1 | AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS (US) | 2004-12-16 | — | — | WO | disclosed |
| US-6670433-B2 | Useful as molding resins | E. I. DU PONT DE NEMOURS AND COMPANY | 2003-12-30 | — | — | US | disclosed |
| US-20030055186-A1 | Polymers of substituted cyclopentenes | MCLAIN STEPHAN J (US) | 2003-03-20 | — | — | US | disclosed |
| US-6258908-B1 | Polymers of substituted cyclopentenes | E. I. DU PONT DE NEMOURS AND COMPANY | 2001-07-10 | — | — | US | disclosed |
| EP-1068247-A2 | POLYMERS OF SUBSTITUTED CYCLOPENTENES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2001-01-17 | — | — | EP | disclosed |
| WO-1999050320-A2 | POLYMERS OF SUBSTITUTED CYCLOPENTENES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1999-10-07 | — | — | WO | disclosed |
| US-3946081-A | OXIDATION CATALYSTS, GROUP V, VI, OR VII OXIDES | BAYER AKTIENGESELLSCHAFT (DT) | 1976-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221478-A1 | DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | CTSF, CTSZ, CTSS | ALDH1A1 1867/4885 |
| US-20110172310-A1 | DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | CTSF, CTSZ, CTSS | ALDH1A1 1867/4885 |
| US-20140018421-A1 | DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | CTSF, CTSZ, CTSS | ALDH1A1 1867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.